Inositol (Myo-Inositol): PCOS, Insulin Sensitivity & Mental Health — A Research-Backed Guide
⚡ 60-Second Summary
Inositol — specifically myo-inositol — is a carbocyclic polyol that acts as a critical second messenger in insulin receptor signaling and numerous other signaling cascades. It is sometimes called vitamin B8, though it is not a true vitamin since the body can synthesize it from glucose. The most well-supported use is PCOS (polycystic ovary syndrome): myo-inositol at 2–4 g/day improves ovulatory function, reduces androgens, and improves insulin sensitivity, as demonstrated in multiple RCTs and a 2016 meta-analysis by Unfer et al.
Key forms: Myo-inositol (most abundant; 2–4 g/day for PCOS, 12–18 g/day for mental health trials) and D-chiro-inositol (DCI) (300–600 mg/day for androgen reduction; derived from myo-inositol in tissues). Combinations at a 40:1 myo:DCI ratio (e.g., 1,900 mg myo + 50 mg DCI) show additive PCOS benefits in several trials.
Safety: Well-tolerated at PCOS doses; mild GI effects at high doses (12+ g/day). Not to be confused with inositol hexanicotinate (flush-free niacin — a different product entirely).
What is inositol?
Inositol is a six-carbon cyclohexane polyol (same molecular formula as glucose: C6H12O6, but arranged in a ring with six hydroxyl groups). It exists as nine stereoisomers, of which myo-inositol is overwhelmingly the most abundant in nature and the human body. The body can synthesize myo-inositol from glucose-6-phosphate via inositol-3-phosphate synthase. Dietary sources include fruits (especially citrus), beans, grains (especially in the bran), and nuts. Typical dietary intake is 1–2 g/day.
Inositol is a building block of phosphatidylinositols (PI) — membrane phospholipids that serve as substrates for phospholipase C (PLC) and PI3-kinase. When PI(4,5)P2 is cleaved by PLC (activated by numerous G-protein coupled receptors including insulin, serotonin, and others), it generates inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) — two critical second messengers. This is why inositol depletion has downstream effects on insulin signaling, serotonin receptor activity, and multiple hormonal pathways.
Evidence-based benefits of inositol supplementation
1. PCOS — insulin sensitization and ovulatory function restoration
This is inositol's strongest evidence base. Women with PCOS have impaired myo-inositol to D-chiro-inositol conversion in ovarian granulosa cells and reduced inositol-based insulin signaling. Myo-inositol supplementation at 2–4 g/day has been shown in multiple RCTs to:
- Restore ovulatory cycles in anovulatory women (improved menstrual regularity)
- Reduce fasting insulin and HOMA-IR (insulin resistance index)
- Lower free testosterone and LH:FSH ratio
- Improve oocyte quality in women undergoing IVF
- Reduce androgen-related symptoms (hirsutism, acne) modestly
A 2016 Cochrane-adjacent meta-analysis by Unfer et al. pooling 13 RCTs (n≈1,200) confirmed significant benefits on insulin sensitivity and ovulatory function. Head-to-head trials against metformin have shown comparable or superior insulin sensitization with better tolerability (less GI distress). Myo-inositol is endorsed in PCOS management guidelines in Italy and several European countries.
2. Mental health — OCD and panic disorder (small trials)
The inositol depletion hypothesis proposes that lithium's therapeutic effects (in bipolar disorder) are partly mediated by inositol depletion — and that supplementing inositol could modulate serotonergic and adrenergic signaling. Small RCTs:
- OCD: Fux et al. (1996, n=13) — myo-inositol 18 g/day for 6 weeks significantly reduced Yale-Brown OCD scale scores vs placebo; small replication attempts have had mixed results
- Panic disorder: Palatnik et al. (2001, n=20) — 18 g/day for 1 month reduced frequency and severity of panic attacks, comparable to fluvoxamine effect with fewer side effects
- Depression: Trials have been largely negative; inositol for MDD does not appear efficacious
Caution: Sample sizes are small (13–40 participants), and results have not been consistently replicated in larger studies. Inositol for mental health is exploratory — it is not a substitute for established psychiatric treatment and should be discussed with a psychiatrist.
3. Gestational diabetes prevention
A 2018 double-blind RCT (D'Anna et al., n=220 overweight pregnant women) showed that myo-inositol 2 g/day plus folic acid from the first trimester significantly reduced gestational diabetes incidence compared to folic acid alone (11.6% vs 27.4%). A 2022 meta-analysis confirmed these findings across several trials. This is a promising emerging use, though guidelines have not yet universally incorporated it.
4. Metabolic syndrome and insulin resistance
Beyond PCOS, myo-inositol shows benefits in men and non-PCOS women with metabolic syndrome: modest reductions in blood pressure, triglycerides, and improved insulin sensitivity at 4 g/day over 6–12 months. Evidence is less robust than for PCOS but biologically consistent.
PCOS: understanding the inositol mechanism
In normal ovarian physiology, FSH (follicle-stimulating hormone) drives local conversion of myo-inositol to D-chiro-inositol via the enzyme epimerase. This DCI then activates specific insulin sensitizing second-messenger pathways in granulosa cells. In PCOS, this conversion is impaired — DCI is deficient locally even when myo-inositol is adequate. This leads to ovarian insulin resistance, hyperandrogenemia, and impaired follicle development.
Supplemental myo-inositol provides the substrate for this conversion. The 40:1 myo:DCI ratio (approximately the physiological ratio in plasma) has been proposed as optimal for combined ovarian and systemic insulin sensitization. DCI alone at high doses can paradoxically impair oocyte quality in some studies — hence the importance of the ratio-based approach.
Inositol forms compared
| Form | Primary use | Typical dose | Notes |
|---|---|---|---|
| Myo-inositol | PCOS, mental health, gestational diabetes prevention | 2–4 g/day (PCOS); 12–18 g/day (mental health trials) | Most abundant form; preferred for PCOS monotherapy. Available as powder (most economical and best absorbed) or capsule. |
| D-chiro-inositol (DCI) | PCOS androgen reduction; insulin sensitization | 300–600 mg/day | Derived from myo-inositol by tissue epimerase. Lower doses than myo-inositol needed. High-dose DCI alone may impair oocyte quality — use in combination with myo-inositol. |
| 40:1 myo:DCI combination | PCOS (combined ovarian and systemic support) | 1,900 mg myo + 50 mg DCI (= 40:1); twice daily | Mimics physiological plasma ratio. Several RCTs show additive benefit vs myo-inositol alone. Common in branded PCOS formulas. |
| Inositol hexaphosphate (IP6) | Antioxidant; immune modulation research | 1–4 g/day in research | Phytic acid / IP6 has distinct properties from free myo-inositol. Chelates minerals (iron, zinc) — may reduce their absorption. Different evidence base from myo-inositol; not the same product. |
How much inositol should you take?
- PCOS (ovulatory function, insulin sensitivity): 2–4 g myo-inositol per day; often split as 2 g twice daily with meals. Typical trial duration: 3–6 months before evaluating response.
- PCOS with DCI combination (40:1 ratio): 1,900 mg myo + 50 mg DCI, twice daily; equal to 3,800 mg myo + 100 mg DCI/day
- Panic disorder / OCD (research doses): 12–18 g/day of myo-inositol — these are pharmacological doses not suitable for self-prescription; should be under psychiatric supervision
- Gestational diabetes prevention: 2 g myo-inositol + 200 mcg folic acid twice daily (based on D'Anna trial protocol)
- General metabolic support: 2–4 g/day myo-inositol
Powder form dissolved in water is preferred over capsules for high-dose use — it is more economical and dissolves readily. Take with meals for best tolerability.
Safety and side effects
Myo-inositol has an excellent safety profile at PCOS doses (2–4 g/day):
- GI effects: Nausea, flatulence, loose stools, and diarrhea are the most common side effects, typically at higher doses (12+ g/day). Starting low (1 g/day) and titrating up over 1–2 weeks reduces GI discomfort.
- Mental health doses (12–18 g/day): GI side effects are more pronounced. Rarely, worsening of bipolar disorder symptoms has been reported — consistent with the inositol depletion hypothesis (supplementing inositol may partially counteract lithium's mechanism).
- Pregnancy: Myo-inositol at 2–4 g/day has been used safely in pregnancy trials (gestational diabetes prevention); data across hundreds of subjects shows no teratogenicity. Still, discuss with an OB before using in pregnancy.
- No established UL — it is naturally synthesized by the body and present in normal metabolism
Drug and nutrient interactions
- Lithium: Inositol may partially counteract lithium's mechanism of action (lithium inhibits inositol monophosphatase, depleting inositol as a proposed therapeutic mechanism in bipolar disorder). Use of high-dose inositol in people on lithium should be discussed with a psychiatrist.
- Metformin: May be used alongside metformin for PCOS; some trials have compared them head-to-head. The combination has not shown clinically significant interaction; additive benefit is theoretically possible but not well-studied.
- Clomiphene (for ovulation induction): Some protocols combine myo-inositol with clomiphene in PCOS — myo-inositol may improve clomiphene response in resistant cases. This combination should be managed by a reproductive endocrinologist.
- IP6 (inositol hexaphosphate): IP6 chelates iron, zinc, and calcium; taking IP6 with meals can reduce mineral absorption from food. This applies specifically to IP6/phytic acid, not to plain myo-inositol.
Check our free interaction checker for additional combinations.
Who might benefit from inositol supplementation
| Most likely to benefit | Uncertain or limited benefit |
|---|---|
| Women with PCOS seeking to improve ovulatory function and insulin sensitivity | Men without insulin resistance or metabolic syndrome |
| Women with PCOS undergoing IVF (improved oocyte quality in trials) | People with depression (inositol trials for MDD largely negative) |
| Overweight pregnant women at risk for gestational diabetes (with OB supervision) | Those seeking short-term anxiety relief (high doses needed; not suitable for self-prescription) |
| People with panic disorder or OCD interested in adjunctive support (small trial evidence; under psychiatric supervision) | People with bipolar disorder on lithium (may counteract lithium mechanism) |
Frequently asked questions
What is the best form of inositol for PCOS?
Myo-inositol at 2–4 g/day is the best-supported form for PCOS. Many practitioners now recommend the 40:1 myo:DCI combination (e.g., 1,900 mg myo + 50 mg DCI, twice daily) for combined ovarian and systemic insulin sensitization. Pure DCI at high doses may reduce oocyte quality — so it should be used in combination with myo-inositol rather than alone for fertility goals.
How long does myo-inositol take to work for PCOS?
Most PCOS trials show measurable improvements in menstrual cycle regularity and hormonal markers within 3–6 months. Some women report menstrual cycle normalization within 1–2 months. Insulin sensitivity improvements (HOMA-IR reduction) are typically demonstrable at the 3-month blood test. A minimum 3-month trial at the full dose is appropriate before assessing response.
Is inositol safe during pregnancy?
Myo-inositol at 2–4 g/day alongside folic acid has been studied specifically in pregnant women for gestational diabetes prevention — multiple RCTs show it is safe and well-tolerated in this context. It is not considered teratogenic. However, pregnancy supplementation decisions should always be made with your obstetrician, who can assess your individual risk and benefit profile.
Can inositol replace metformin for PCOS?
Head-to-head trials suggest myo-inositol produces comparable insulin sensitization to metformin (500–1,500 mg/day) with better GI tolerability. For mild-to-moderate PCOS without severe insulin resistance, myo-inositol is a reasonable first-line approach. For women with significant insulin resistance (fasting glucose >100 mg/dL, HOMA-IR >3.5), metformin or combined therapy may be more effective. This decision should be made with the treating clinician.
Is inositol the same as inositol hexanicotinate (flush-free niacin)?
No. Inositol hexanicotinate (IHN), sold as flush-free niacin, is a compound where six niacin molecules are chemically esterified to one inositol. The two products have entirely different uses, mechanisms, and evidence bases. Plain myo-inositol is not a niacin compound and has no flush-free niacin properties. See the flush-free niacin page for that discussion.
Related ingredients and articles
Flush-Free Niacin (Inositol Hexanicotinate)
A completely different product that contains inositol chemically bound to niacin — distinct evidence and uses.
Active B Complex
B vitamins that support the methylation and metabolic pathways relevant to PCOS management.
DIM (Diindolylmethane)
Another supplement with hormonal metabolism effects — complementary to inositol in PCOS discussions.
Methylated Multivitamin
Broad nutritional support that may complement inositol therapy for PCOS and metabolic health.
Disclaimer: This information is for educational purposes only and should not replace medical advice. Always consult a qualified healthcare provider before starting any supplement, especially if you have a medical condition, are pregnant, or take prescription medications. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.